Literature DB >> 25442040

Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists.

Minh-Phuong Huynh-Le1, Zhe Zhang2, Phuoc T Tran1, Theodore L DeWeese1, Daniel Y Song3.   

Abstract

PURPOSE: To measure concordance among genitourinary radiation oncologists in using the National Cancer Institute Common Toxicity Criteria (NCI CTC) and Radiation Therapy Oncology Group (RTOG) grading scales to grade rectal bleeding. METHODS AND MATERIALS: From June 2013 to January 2014, a Web-based survey was sent to 250 American and Canadian academic radiation oncologists who treat prostate cancer. Participants were provided 4 case vignettes in which patients received radiation therapy and developed rectal bleeding and were asked for management plans and to rate the bleeding according to NCI CTC v.4 and RTOG late toxicity grading (scales provided). In 2 cases, participants were also asked whether they would send the patient for colonoscopy. A multilevel, random intercept modeling approach was used to assess sources of variation (case, respondent) in toxicity grading to calculate the intraclass correlation coefficient (ICC). Agreement on a dichotomous grading scale (low grades 1-2 vs high grades 3-4) was also assessed, using the κ statistic for multiple respondents.
RESULTS: Seventy-two radiation oncologists (28%) completed the survey. Forty-seven (65%) reported having either written or been principal investigator on a study using these scales. Agreement between respondents was moderate (ICC 0.52, 95% confidence interval [CI] 0.47-0.58) when using NCI CTC and fair using the RTOG scale (ICC 0.28, 95% CI 0.20-0.40). Respondents who chose an invasive management were more likely to select a higher toxicity grade (P<.0001). Using the dichotomous scale, we observed moderate agreement (κ = 0.42, 95% CI 0.40-0.44) with the NCI CTC scale, but only slight agreement with the RTOG scale (κ = 0.19, 95% CI 0.17-0.21).
CONCLUSION: Low interrater reliability was observed among radiation oncologists grading rectal bleeding using 2 common scales. Clearer definitions of late rectal bleeding toxicity should be constructed to reduce this variability and avoid ambiguity in both reporting and interpretation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25442040      PMCID: PMC4276525          DOI: 10.1016/j.ijrobp.2014.08.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  The recording of morbidity related to radiotherapy.

Authors:  S Dische; M F Warburton; D Jones; E Lartigau
Journal:  Radiother Oncol       Date:  1989-10       Impact factor: 6.280

2.  Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.

Authors:  Jacqueline Vuky; Huong T Pham; Sarah Warren; Erika Douglass; Kasra Badiozamani; Berit Madsen; Alex Hsi; Guobin Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-28       Impact factor: 7.038

3.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 4.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.

Authors:  A Trotti; R Byhardt; J Stetz; C Gwede; B Corn; K Fu; L Gunderson; B McCormick; M Morrisintegral; T Rich; W Shipley; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

5.  Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.

Authors:  Kevin Forsythe; Seth Blacksburg; Nelson Stone; Richard G Stock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-16       Impact factor: 7.038

6.  Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

Authors:  M D Brundage; J L Pater; B Zee
Journal:  J Natl Cancer Inst       Date:  1993-07-21       Impact factor: 13.506

7.  Scoring of treatment-related late effects in prostate cancer.

Authors:  Jacqueline E Livsey; Jacqueline Routledge; Meriel Burns; Rick Swindell; Susan E Davidson; Richard A Cowan; John P Logue; James P Wylie
Journal:  Radiother Oncol       Date:  2002-11       Impact factor: 6.280

8.  Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy.

Authors:  Jeremy G Price; Nelson N Stone; Richard G Stock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-01       Impact factor: 7.038

9.  Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.

Authors:  Fabrice Denis; Pascal Garaud; Etienne Bardet; Marc Alfonsi; Christian Sire; Thierry Germain; Philippe Bergerot; Béatrix Rhein; Jacques Tortochaux; Patrick Oudinot; Gilles Calais
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-01-01       Impact factor: 7.038

Review 10.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin
Journal:  Semin Radiat Oncol       Date:  2003-07       Impact factor: 5.934

View more
  6 in total

1.  Using electronic medical record data to report laboratory adverse events.

Authors:  Tamara P Miller; Yimei Li; Kelly D Getz; Jesse Dudley; Evanette Burrows; Jeffrey Pennington; Azada Ibrahimova; Brian T Fisher; Rochelle Bagatell; Alix E Seif; Robert Grundmeier; Richard Aplenc
Journal:  Br J Haematol       Date:  2017-02-01       Impact factor: 6.998

2.  Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?

Authors:  Mirko Nitsche; Werner Brannath; Matthias Brückner; Dirk Wagner; Alexander Kaltenborn; Nils Temme; Robert M Hermann
Journal:  Br J Radiol       Date:  2016-12-12       Impact factor: 3.039

3.  Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study.

Authors:  Peter Paximadis; Matthew Schipper; Martha Matuszak; Mary Feng; Shruti Jolly; Thomas Boike; Inga Grills; Larry Kestin; Benjamin Movsas; Kent Griffith; Gregory Gustafson; Jean Moran; Teamour Nurushev; Jeffrey Radawski; Lori Pierce; James Hayman
Journal:  Pract Radiat Oncol       Date:  2017-07-19

4.  Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease.

Authors:  Zhiyuan Wang; Chunyan Wang; Xiaoli Yang
Journal:  Exp Ther Med       Date:  2017-11-24       Impact factor: 2.447

5.  Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.

Authors:  Tamara P Miller; Yimei Li; Marko Kavcic; Andrea B Troxel; Yuan-Shun V Huang; Lillian Sung; Todd A Alonzo; Robert Gerbing; Matt Hall; Marla H Daves; Terzah M Horton; Michael A Pulsipher; Jessica A Pollard; Rochelle Bagatell; Alix E Seif; Brian T Fisher; Selina Luger; Alan S Gamis; Peter C Adamson; Richard Aplenc
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

6.  Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.

Authors:  Li Chen; Ping Bai; Xiangyi Kong; Shaolong Huang; Zhongzhao Wang; Xiangyu Wang; Yi Fang; Jing Wang
Journal:  Front Cell Dev Biol       Date:  2021-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.